FOCUS: OPHTHALMOLOGY
FDA slaps vision loss warning on GLP-1s
Lawyers representing complainants in personal injury lawsuits alleging vision loss associated with GLP-1 medications have welcomed the Food and Drug Administration’s (FDA) directive that the popular weight loss drugs must now carry warnings that they can increase the risk of vision loss, reports MedicalBrief.
In a statement released yesterday, Jonathan Orent from US-based Motley Rice Attorneys, and co-lead counsel in non-arteritic anterior ischaemic optic neuropathy (NAION)-related litigation, said doctors have, for too long, lacked a warning about the potentially blinding...


